Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.63 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.63 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.63 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 6/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | BID | P55957 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6260223 | 0.90 | PTGER4 (0.67) | PTGER1PTGER4PTGER3PTGER2TSHR | |
| SCHEMBL1982703 | 0.86 | HDAC8 (0.67) | PTGER1PTGER4PTGER3PTGER2TSHR | |
| SCHEMBL9511673 | 0.83 | RARB (0.61) | TSHRRARBBIDBCL2L1MCL1 | |
| SCHEMBL6260082 | 0.83 | TSHR (0.58) | PTGER1PTGER4PTGER3PTGER2TSHR | |
| SCHEMBL1980515 | 0.82 | RARB (0.65) | PTGER1PTGER4PTGER3PTGER2HDAC8 | |
| SCHEMBL8319817 | 0.82 | PTGER1 (0.61) | PTGER1PTGER4PTGER3PTGER2TSHR | |
| SCHEMBL2743520 | 0.81 | HDAC1 (0.68) | PTGER1PTGER4PTGER3PTGER2HDAC8 | |
| SCHEMBL2402134 | 0.81 | HDAC1 (0.68) | PTGER1PTGER4PTGER3PTGER2HDAC8 | |
| SCHEMBL6263046 | 0.81 | PTGER1 (0.59) | PTGER1PTGER4PTGER3PTGER2TSHR | |
| SCHEMBL8744299 | 0.81 | PTGER1 (0.59) | PTGER1PTGER4PTGER3PTGER2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0752421-B1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| US-6787562-B2 | ANALGESICS; OSTEOPOROSIS | ZENECA LTD. (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | SYNGENTA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| US-6057345-A | ANTAGONISTS OF THE PAIN ENHANCING EFFECTS OF E-TYPE PROSTAGLANDINS; USED IN PAIN RELIEF | ZENECA LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | PTGER1, PTGDR, PTGER2 | PTGER1 1/4885PTGER4 4/4885PTGER3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.